Business Context and Reporting Period
Company: Athira Pharma, Inc. (Note: Input metadata referenced "Leonabio," but the filing text identifies the registrant as Athira Pharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company's lead drug candidate is ATH-1105, currently in development for Amyotrophic Lateral Sclerosis (ALS). Following the failure of its previous lead candidate, fosgonimeton, to meet primary endpoints in the LIFT-AD Phase 2/3 trial in September 2024, the company paused fosgonimeton development and shifted focus to ATH-1105. The company is currently exploring strategic alternatives to maximize stockholder value.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Three Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(16,109) | $(53,196) | $(6,966) |
| Net Loss Per Share (Basic & Diluted) | $(0.41) | $(1.39) | $(0.18) |
| Operating Expenses | $16,827 | $55,715 | $7,291 |
| Research & Development (R&D) | $7,963 | $43,390 | $3,661 |
| General & Administrative (G&A) | $8,864 | $12,325 | $3,630 |
| Cash, Cash Equivalents & Investments | $29,823 | $51,275 | $29,823 |
| Accumulated Deficit | $(422,255) | $(362,402) | $(422,255) |
| Net Cash Used in Operating Activities | $(21,664) | $(48,134) | N/A |
Material Changes vs. Prior Period
- Significant Reduction in Expenses: Total operating expenses decreased by approximately 70% ($38.9 million) for the six months ended June 30, 2025, compared to the same period in 2024. This was driven primarily by a $25.7 million decrease in fosgonimeton program costs following the decision to pause its development.
- R&D Spend Shift: R&D expenses dropped 82% year-over-year. Direct costs for fosgonimeton fell by 93%, while spending on the lead candidate ATH-1105 decreased by 34% as the company transitions to a leaner operational model.
- Liquidity Position: Cash, cash equivalents, and investments decreased from $51.3 million at June 30, 2024, to $29.8 million at June 30, 2025, reflecting ongoing operational burn despite reduced expenses.
- Accrued Liabilities: Accrued liabilities decreased significantly from $12.4 million to $2.4 million, largely due to the settlement of restructuring-related severance costs incurred in late 2024.
Guidance, Outlook, and Risks
- Strategic Review: The company is actively exploring strategic alternatives, including potential mergers, acquisitions, or asset sales, to maximize stockholder value. There is no assurance a transaction will be completed.
- Liquidity Outlook: Management estimates that existing cash and investments ($29.8 million) are sufficient to fund operations for at least the next 12 months. However, substantial additional funding will be required to complete the development and commercialization of ATH-1105.
- Nasdaq Compliance: The company transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market in April 2025 to gain an additional 180-day grace period (until October 13, 2025) to regain compliance with the $1.00 minimum bid price requirement. Stockholders approved a reverse stock split in May 2025, but it has not yet been effected.
- Key Risks:
- Development Risk: ATH-1105 is in early clinical stages; there is no guarantee it will prove safe or effective.
- Capital Needs: Failure to raise additional capital could force the company to delay, reduce, or eliminate development programs.
- Regulatory & Market Risk: The company faces significant competition and regulatory hurdles in the neurodegenerative disease space, which has a history of limited product development success.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $29.8 million cash balance against the current burn rate and the timeline for the next ATH-1105 clinical trial data readout.
- Strategic Process Status: Monitor for updates on the strategic review process, including any definitive agreements for mergers, acquisitions, or asset sales.
- Nasdaq Compliance: Track the stock price relative to the $1.00 minimum bid requirement and the potential implementation of the approved reverse stock split before the October 13, 2025 deadline.
- ATH-1105 Progress: Confirm the timeline and design for the upcoming ALS clinical trial, as the company's future value is heavily dependent on this single asset.
- Legal Proceedings: Review ongoing or potential litigation related to prior research misconduct claims involving former leadership, as noted in the risk factors.